PODD— AI Stock Forecast & Price Targets
Published 7/15/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live PODD price forecast →
PODD is a high-quality diabetes device franchise (71% gross margin, 23% ROE, 32% TTM revenue growth) trading at ~$162 after a ~44% YTD drawdown, offering genuine quality-on-sale at ~20x forward earnings and PEG 0.74. However, the stock remains ~34% below its SMA200, faces a binary Aug 5 earnings print with unquantified FDA Class I recall liability, and prior calls to $185+ have not printed — the correct read is base-building in the $155-$165 range, not trend reversal. Accumulate on weakness with tight risk controls, but no aggressive sizing into the print.
1-4 week view: Range-trade the $150-$165 consolidation into Aug 5 earnings. Do NOT add aggressively into the print — this is a binary event with gap risk both directions and the first real look at FDA recall drag. Existing positions can hold; new entries preferred on tests of $150-$155 with tight stops below $145 (below $140 invalidates the base). Take partials into $165 range top. Explicit earnings stance: NEUTRAL/DEFENSIVE — the guide raise sets a higher bar and recall liability isn't quantified. No new swing trades sized for the print.
1-6 month view: Accumulate framework — quality-on-sale at ~20x forward with 21-23% guided growth is genuinely attractive if the recall drag is manageable. Expected return range: -15% to +25% (bear $138, base $175, bull $210). Key catalysts: (1) Aug 5 print — revenue, GM, recall charge quantification, forward guide; (2) reclaim of $180 with volume as trend-change confirmation; (3) sell-side revision stabilization. What would change my mind: a clean print with contained recall reserves + Omnipod 5 momentum reaccelerating pushes me to a full BUY; a soft guide + unquantified liability + break of $138 flips to HOLD/AVOID.
1-3 year view: If management's $4.8B 2029 revenue target is credible, PODD is a compounder — Omnipod 5 platform, Type 2/pediatric expansion, international rollout (Spain/EU), and Omnipod Discover data platform all extend the runway beyond core Type 1. At 20x forward on doubling revenue, the math works to $250-$300. Biggest structural risk: GLP-1 secular headwind potentially shrinking the insulin-dependent Type 2 pool over 3-5 years, combined with competitive pressure from Tandem/Medtronic and integrated CGM+pump platforms from Abbott/Dexcom. Recall liability could also compound into ongoing litigation that pressures margins.
Fundamentals remain elite for a mid-cap medtech: Q1'26 revenue of $761.7M (+33.9% YoY), gross margin 69.5%, operating margin 16.0%, net margin 12.0%. TTM revenue $2.90B (+31.9%), ROE 23%, ROIC 13.6%, and full-year guide was raised to 21-23% growth. The balance sheet is solid — $480M cash vs $948M debt, current ratio 2.49, working capital $1.02B, and TTM operating cash flow $619M with FCF of $253M (FCF was compressed by a $149M capex spike in Q4'25 that needs to prove non-recurring). Forward P/E of 19.8x and PEG of 0.74 look inexpensive for a 30%+ grower with 71% gross margins. What's working: Omnipod 5 platform scaling, algorithm OTA upgrades, Type 2/pediatric TAM expansion. What's broken: TTM EPS is down 24.9% YoY reflecting margin/investment digestion, Q4'25 capex spike and Q1'26 equity decline ($1,515M → $1,303M) hint at buybacks or one-off charges that need clarity, and the unquantified FDA Class I recall liability isn't in numbers yet.
The tape is broken across all timeframes above the 1h. Weekly chart shows a full round-trip from ~$340 highs (Jan) to $138.79 low, with current price $159.12 sitting -55% off 52-week high and -34% below SMA200. Daily chart confirms a multi-month downtrend from $290 to $138 with only a shallow bounce; the $138-$150 zone has held as support through multiple tests, but no reclaim of $180 pivot has occurred. Short-term is more constructive — 1h shows a $155-$165 consolidation range, RSI 52.9 is neutral, SMA20 (+3.2%) and SMA50 (+3.6%) are both below price, and the past month is +6.7%. However the 1h model forecast is aggressively bearish to $144 while the 4h/1d/1wk forecasts show violent up-moves to $244-$262 — these are inconsistent and the weekly model has been beaten by the naive baseline (17% vs 67% directional accuracy), so the upside forecast should be heavily discounted. Key levels: support $138-$140 (must hold), $150 (near-term), resistance $165 (range top), $180 (trend-change gate), $220-$243 (SMA200 + analyst cluster).
Signal: the Calm partnership (Jul 14) is a soft brand/retention play, not a revenue catalyst; more meaningful is the Truist reiteration of Buy with a lowered target to $210 from $219 — sell-side is still cutting numbers but staying constructive. The Aug 5 pre-market earnings print is the dominant near-term catalyst, with the June 19 full-year guide raise (from 20-22% to 21-23%) signaling management confidence but also setting a higher bar. The recent ClearBridge commentary framing PODD as falling with the broader medtech sector suggests part of the drawdown is sector beta, not company-specific — supportive for a mean-reversion thesis if medtech sentiment turns. Noise: the 8-K from June 25 (executive change + Reg FD) warrants monitoring but no financial impact is disclosed. Congressional sales in April/May by a spouse account are stale and small. Social sentiment is thin (only 15 Stocktwits + 4 X messages, mostly bullish but mixed with cross-pumping of $MODD) — not a reliable signal here. No fresh recall quantification has hit the tape, meaning that liability remains a Q2 print unknown.
- Full-year 2026 revenue guide raised to 21-23% growth (from 20-22%) on Jun 19, 2026 — management confidence in sales momentum
- Q1'26 revenue $761.7M (+33.9% YoY) and adjusted EPS $1.42 beat consensus by 19.3%
- FDA-cleared Omnipod 5 algorithm upgrade (Jul 2026) enhancing closed-loop functionality — supports adoption and TAM defense
- Type 2 insulin-intensive and pediatric label expansions materially widening TAM beyond core Type 1
- International rollout including Spain/EU with bundled Omnipod Discover data platform opening recurring/software layer
- Management's $4.8B 2029 revenue target implies durable double-digit growth vs $2.9B TTM
- Calm partnership launching global content collection by Oct 14, 2026 — brand/retention play in diabetes wellness
- Unquantified FDA Class I recall liability — warranty, remediation, and litigation reserves not yet in the numbers
- Aug 5 earnings is a binary event with gap risk both directions — first real read on recall drag
- Broken weekly trend — price ~34% below SMA200 (~$243) with no confirmed reversal; prior bounce attempts have all failed
- Sell-side revision trend still negative (Truist cut to $210 from $219) despite Buy ratings maintained
- Class action lawsuit deadline Aug 31, 2026 — potential headline risk and reserve disclosure
- GLP-1 secular headwind potentially shrinking insulin-dependent Type 2 population over 3-5 years
- Competitive pressure from Tandem, Medtronic, and integrated CGM+pump platforms (Abbott/Dexcom)
- TTM EPS down 24.9% YoY and Q1'26 stockholders' equity down $212M sequentially — capital allocation clarity needed
- Weekly forecast model has been beaten by naive baseline (17% vs 67% directional accuracy) — heavily discount aggressive upside projections
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord